VMD: Librela benefits outweigh risks for most dogs
If your dog is slowing down on winter walks, you may have heard of Librela, an injection used to ease osteoarthritis pain in dogs. The UK's Veterinary Medicines Directorate (VMD) has completed an in-depth assessment and says the medicine's benefits continue to outweigh the risks for most dogs treated.
Why this matters for you: medicines used in animals are watched after approval, not just before. The VMD says it is aware of concerns shared by some owners and vets, and it has analysed UK safety data to check whether the balance between benefit and risk still holds.
Librela is a monoclonal antibody medicine. In simple terms, that means a lab-made protein designed to target a very specific signal involved in pain. Like any medicine, it can cause side effects in some patients, and the fact it is an antibody does not remove that possibility.
In its review, the VMD looked closely at reports of death, of arthritis progressing faster than expected, and of accidental human exposure. Routine monitoring also covered reports of lack of effect as well as recumbency, muscle weakness, lameness and tremor. These categories help the regulator spot patterns rather than rely on single stories.
Product information is being updated as evidence grows. In January 2026 the VMD added the terms immune-mediated polyarthritis, paresis and paralysis to Librela's official product information. Vets are advised to check the Summary of Product Characteristics (SPC) before prescribing, and owners should read the package leaflet.
How common are problems? According to the VMD, reports of adverse events in the UK after Librela administration are uncommon, seen in 1 to 10 animals per 1,000 estimated animals treated. Reports of death are rare, occurring in 1 to 10 animals per 10,000 estimated animals treated. Many dogs, the regulator notes, experience marked improvement in mobility and comfort.
Working out cause and effect is not always straightforward. Librela is mainly used in older dogs, many of whom already have other health conditions or take several medicines. That background makes it harder to be certain that a reported event was caused by Librela alone, and it is a factor vets weigh up when discussing options with you.
If you are a veterinary professional, the VMD asks that you read the SPC carefully, monitor patients during treatment, and report suspected adverse events directly to Zoetis, the company responsible for Librela. The company, as the Marketing Authorisation Holder, must operate a system to collect and evaluate safety reports and provide them to the VMD within 30 days.
If you are a dog owner, talk to your vet if you have questions about treatment, and contact them immediately if your dog seems unwell after an injection. You can also report side effects to Zoetis. When you do, include as much detail as possible: your dog's medical history, any other medicines, dates and doses given, and for orthopaedic cases, any imaging from before and after treatment.
Pharmacovigilance is the term for this ongoing safety monitoring. The VMD says it will keep reviewing new data, write to vets with detailed findings from this assessment, and update the product information again if needed. You can follow official updates via the VMD's Product Information Database and its safety update notices, while vets can also check monthly round-ups in the Vet Record.
Librela was first authorised for use in the UK in November 2020. The VMD's position today is not a blank cheque for any medicine; it is a reminder to combine evidence-based care with careful observation. For classrooms and clinics alike, this is a live case study in how we weigh benefits and risks, stay alert to new signals, and report clearly so dogs get the best possible chance at a comfortable life.